Details of Drug

Drug General Information (ID: D0523)
Drug Name	Doxapram
Drug Type	Small molecule
Drug Synonymous	Docatone; Dopram; Doxapramum; Doxapram HCL; Doxapram hydrochloride; Docatone (TN); Dopram (TN); Doxapram (INN); Doxapram [USP:JAN]; Doxapramum [INN-Latin]; (+-)-doxapram; 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone; 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one; 1-ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-one; 2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-(9CI) Click to Show/Hide
Disease Class	CB40-CB7Z: Respiratory system disease
Therapeutic Class	Cns Stimulants
Structure
Structure	3D Structure		2D Structure
Formula	C24H30N2O2
InChI	1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3
InChIKey	XFDJYSQDBULQSI-UHFFFAOYSA-N
Canonical SMILES	CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4
External Link
	Pubchem ID	3156
	CAS Number	309-29-5
	CHEBI ID	681848
	TTD ID	D0M7BT

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM003 Affected organization distribution AM004 Affected intra/extra-hepatic metabolism AM006 Pharmacodynamic additive effects BM014 Interference of cell/tissue uptake BM018 Non-CYP450 enzyme inhibition BM041 Additive hypertensive effects BM061 Increased risk of hyperpyrexia BM069 Increased risk of lowers seizure threshold
Relation Graph

Full list of drugs interacting with Doxapram
Affected organization distribution
	Interference of cell/tissue uptake					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0829		Iobenguane (I-131)	C8H10IN3	60860	Major		Inter Info	[21]
D1821		Iobenguane (I-123)	C8H10IN3	60860	Moderate		Inter Info	[92], [93], [94]
Affected intra/extra-hepatic metabolism
	Non-CYP450 enzyme inhibition					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1437		Safinamide	C17H19FN2O2	131682	Moderate		Inter Info	[99], [27], [28], [19], [16], [100], [30], [31], [32], [101], [33], [53], [37], [102], [45], [75], [98], [103], [48]
Pharmacodynamic additive effects
	Additive hypertensive effects					Drug Num: 33
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0377		Cocaine (nasal)	C17H21NO4	446220	Major		Inter Info	[16], [17], [18]
D0378		Cocaine (topical)	C17H21NO4	446220	Major		Inter Info	[16], [17], [18]
D0600		Esketamine	C13H16ClNO	182137	Major		Inter Info	[19], [20]
D0103		Arformoterol	C19H24N2O4	3083544	Moderate		Inter Info	[40], [42], [83]
D0510		Dobutamine	C18H23NO3	36811	Moderate		Inter Info	[40], [42], [83]
D0517		Dopamine	C8H11NO2	681	Moderate		Inter Info	[40], [42], [83]
D0579		Ephedrine	C10H15NO	9294	Moderate		Inter Info	[40], [42], [83]
D0581		Epinephrine	C9H13NO3	5816	Moderate		Inter Info	[40], [42], [83]
D0691		Formoterol	C19H24N2O4	3410	Moderate		Inter Info	[40], [42], [83]
D0797		Indacaterol	C24H28N2O3	6918554	Moderate		Inter Info	[40], [42], [83]
D0857		Isometheptene	C9H19N	22297	Moderate		Inter Info	[40], [42], [83]
D0859		Isoprenaline	C11H17NO3	3779	Moderate		Inter Info	[40], [42], [83]
D0921		Levonordefrin	C9H13NO3	164739	Moderate		Inter Info	[40], [42], [83]
D0924		Levosalbutamol	C13H21NO3	123600	Moderate		Inter Info	[40], [42], [83]
D1002		Mephentermine	C11H17N	3677	Moderate		Inter Info	[40], [42], [83]
D1013		Metaraminol	C9H13NO2	5906	Moderate		Inter Info	[40], [42], [83]
D1027		Methoxamine	C11H17NO3	6082	Moderate		Inter Info	[40], [42], [83]
D1171		Olodaterol	C21H26N2O5	11504295	Moderate		Inter Info	[40], [42], [83]
D1185		Orciprenaline	C11H17NO3	4086	Moderate		Inter Info	[40], [42], [83]
D1298		Pirbuterol	C12H20N2O3	4845	Moderate		Inter Info	[40], [42], [83]
D1363		Pseudoephedrine	C10H15NO	7028	Moderate		Inter Info	[40], [42], [83]
D1374		Racepinephrine	C9H13NO3	838	Moderate		Inter Info	[40], [42], [83]
D1385		Rasagiline	C12H13N	3052776	Moderate		Inter Info	[27], [49], [28], [16], [51], [29], [30], [52], [32], [33], [53], [34], [54], [55], [35], [60], [36], [61], [97], [43], [44], [46], [98], [47], [48]
D1414		Ritodrine	C17H21NO3	33572	Moderate		Inter Info	[40], [42], [83]
D1438		Salbutamol	C13H21NO3	2083	Moderate		Inter Info	[40], [42], [83]
D1440		Salmeterol	C25H37NO4	5152	Moderate		Inter Info	[40], [42], [83]
D1554		Terbutaline	C12H19NO3	5403	Moderate		Inter Info	[40], [42], [83]
D1695		Vilanterol	C24H33Cl2NO5	10184665	Moderate		Inter Info	[40], [42], [83]
D0854		Isoetharine	C13H21NO3	3762	Moderate		Inter Info	[40], [42], [83]
D1061		Midodrine	C12H18N2O4	4195	Moderate		Inter Info	[16], [107]
D1153		Norepinephrine	C8H11NO3	439260	Moderate		Inter Info	[40], [42], [83]
D1276		Phenylephrine	C9H13NO2	6041	Moderate		Inter Info	[40], [42], [83]
D1281		Phenylpropanolamine	C9H13NO	26934	Moderate		Inter Info	[40], [42], [83]
	Increased risk of hyperpyrexia					Drug Num: 8
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0853		Isocarboxazid	C12H13N3O2	3759	Major		Inter Info	[27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48]
D0933		Linezolid	C16H20FN3O4	441401	Major		Inter Info	[27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48]
D1036		Methylene blue	C16H18ClN3S	6099	Major		Inter Info	[27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48]
D1211		Ozanimod	C23H24N4O3	52938427	Major		Inter Info	[27], [49], [28], [19], [16], [50], [51], [29], [30], [52], [31], [32], [33], [53], [34], [54], [55], [56], [57], [58], [35], [59], [60], [36], [61], [62], [63], [64], [37], [38], [65], [66], [39], [40], [67], [68], [69], [41], [70], [71], [42], [72], [43], [73], [44], [45], [74], [75], [46], [47], [76], [77], [78], [48]
D1263		Phenelzine	C8H12N2	3675	Major		Inter Info	[27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48]
D1345		Procarbazine	C12H19N3O	4915	Major		Inter Info	[27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48]
D1455		Selegiline	C13H17N	26757	Major		Inter Info	[27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48]
D1620		Tranylcypromine	C9H11N	19493	Major		Inter Info	[27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48]
	Increased risk of lowers seizure threshold					Drug Num: 11
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0220		Bupropion	C13H18ClNO	444	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15]
D0833		Iohexol	C19H26I3N3O9	3730	Major		Inter Info	[22], [23], [24], [25], [26]
D0834		Iopamidol	C17H22I3N3O8	65492	Major		Inter Info	[22], [23], [24], [25], [26]
D1616		Tramadol	C16H25NO2	33741	Major		Inter Info	[79], [14], [13], [80]
D0054		Amifampridine	C5H7N3	5918	Moderate		Inter Info	[81], [82]
D0678		Fluphenazine	C22H26F3N3OS	3372	Moderate		Inter Info	[19], [16]
D0722		Ginkgo biloba	NA	NA	Moderate		Inter Info	[84], [85], [86], [87], [88], [89], [90], [91]
D1287		Picosulfuric acid	C18H15NO8S2	5243	Moderate		Inter Info	[95], [96], [16]
D1308		Polyethylene glycol (3350 with electrolytes)	C2H6O2	174	Moderate		Inter Info	[95], [96], [16]
D1488		Sodium sulfate	Na2O4S	24436	Moderate		Inter Info	[95], [16], [96]
D0932		Lindane	C6H6Cl6	727	Moderate		Inter Info	[104], [105], [106]

References
1	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
2	Sheehan DV, Welch JB, Fishman SM "A case of bupropion-induced seizure." J Nerv Ment Dis 174 (1986): 496-8. [PMID: 3090199]
3	Canadian Pharmacists Association.
4	Product Information. Wellbutrin (bupropion). Glaxo Wellcome, Research Triangle Park, NC.
5	Gittelman DK, Kirby MG "A seizure following bupropion overdose." J Clin Psychiatry 54 (1993): 162. [PMID: 8486598]
6	Product Information. Wellbutrin SR (bupropion). Glaxo Wellcome, Research Triangle Park, NC.
7	James WA, Lippmann S "Bupropion: overview and prescribing guidelines in depression." South Med J 84 (1991): 222-4. [PMID: 1899294]
8	Masco HL, Kiev A, Holloman LC, Batey SR, Johnston JA, Lineberry CG "Safety and efficacy of bupropion and nortriptyline in outpatients with depression." Curr Ther Res Clin Exp 55 (1994): 851-63.
9	Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541]
10	Product Information. Zyban (bupropion). Glaxo Wellcome, Research Triangle Park, NC.
11	Storrow AB "Bupropion overdose and seizure." Am J Emerg Med 12 (1994): 183-4. [PMID: 8161393]
12	Johnston JA, Lineberry CG, Ascher JA, et al. "A 102-center prospective study of seizure in association with bupropion." J Clin Psychiatry 52 (1991): 450-6. [PMID: 1744061]
13	Rosenstein DL, Nelson JC, Jacobs SC "Seizures associated with antidepressants: a review." J Clin Psychiatry 54 (1993): 289-99. [PMID: 8253696]
14	Pisani F, Spina E, Oteri G "Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice." Epilepsia 40(Suppl 10) (1999): S48-56. [PMID: 10609604]
15	Product Information. Aplenzin (buPROPion). sanofi-aventis , Bridgewater, NJ.
16	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17	Thevasagyam M, Jindal M, Allsop P, Oates J "Does epinephrine infiltration in septoplasty make any difference?" Eur Arch Otorhinolaryngol 264 (2007): 1175-8.[PMID: 17530270]
18	Product Information. Cocaine Hydrochloride (cocaine topical). Mallinckrodt Medical Inc, St. Louis, MO.
19	Cerner Multum, Inc. "Australian Product Information.".
20	Product Information. Spravato (esketamine). Janssen Pharmaceuticals, Titusville, NJ.
21	Product Information. Azedra (iobenguane I-131). Progenics Pharmaceuticals, Inc., New York, NY.
22	Product Information. Isovue-M-200 (iopamidol). Bracco Diagnostics Inc, Princeton, NJ.
23	Product Information. Amipaque (metrizamide) Nycomed Inc, Princeton, NJ.
24	Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35. [PMID: 810000]
25	Product Information. Omnipaque 180 (iohexol). Amersham Health, Princeton, NJ.
26	Product Information. Osmovist 240 (iotrolan). Berlex Canada Inc, Lachine, QC.
27	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
28	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
29	FISCHER E, ORLANDO J, LUDMER RL. INFLUENCIA DE METILANFETAMINA, IPRONIACIDA Y TRANILCIPROMINA SOBRE LA DEPRESI'ON PSICOMOTORA ADRENAL'INICA [EFFECT OF METHYLAMPHETAMINE, IPRONIAZID AND TRANYLCYPROMINE ON ADRENALINE PSYCHOMOTOR DEPRESSION]. Prensa Med Argent. 1964;51:1538-1540. [PMID: 14272082]
30	Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
31	De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5. [PMID: 4379192]
32	Elis J, Laurence DR, Mattie H, Prichard BN "Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure." Br Med J 2 (1967): 75-8. [PMID: 6020852]
33	Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
34	Harrison WM, McGrath PJ, Stewart JW, Quitkin F "MAOIs and hypertensive crises: the role of OTC drugs." J Clin Psychiatry 50 (1989): 64-5. [PMID: 2464583]
35	Krisko I, Lewis E, Johnson JE "Severe hyperpyrexia due to tranylcypromine-amphetamine toxicity." Ann Intern Med 70 (1969): 559-64. [PMID: 5775035]
36	Markowitz JS, Patrick KS "Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder." Clin Pharmacokinet 40 (2001): 753-72. [PMID: 11707061]
37	Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7. [PMID: 5655478]
38	Product Information. Adderall (amphetamine-dextroamphetamine) Shire Richwood Pharmaceutical Company, Florence, KY.
39	Product Information. Dexedrine (dextroamphetamine) SmithKline Beecham, Philadelphia, PA.
40	Product Information. Focalin (dexmethylphenidate). Mikart Inc, Atlanta, GA.
41	Product Information. Ritalin (methylphenidate). Novartis Pharmaceuticals, East Hanover, NJ.
42	Product Information. Strattera (atomoxetine). Lilly, Eli and Company, Indianapolis, IN.
43	Product Information. Vyvanse (lisdexamfetamine). Shire US Inc, Florence, KY.
44	Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M "Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs." Ann N Y Acad Sci 107 (1963): 1005-15. [PMID: 13991689]
45	Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36. [PMID: 2510962]
46	Sjoqvist F "Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances." Proc R Soc Med 58 (1965): 967-78. [PMID: 4952963]
47	Smookler S, Bermudez AJ "Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant." Ann Intern Med 11 (1982): 482-4. [PMID: 7114595]
48	Wright SP "Hazards with monoamine-oxidase inhibitors: a persistent problem." Lancet 1 (1978): 284-5. [PMID: 74715]
49	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
50	Coleman AL, Robin AL, Pollack IP, Rudikoff MT, Enger C, Mayer PR "Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine." Arch Ophthalmol 108 (1990): 1264-7. [PMID: 2205182]
51	Cuthbert MF, Greenberg MP, Morley SW "Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors." Br Med J 1 (1969): 404-6. [PMID: 5763957]
52	Davies B, Bannister R, Sever P "Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure: limitations and hazards." Lancet 1 (1978): 172-5. [PMID: 74603]
53	Goulet JP, Perusse R, Turcotte JY "Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions." Oral Surg Oral Med Oral Pathol 74 (1992): 692-7. [PMID: 1359489]
54	Horler AR, Wynne NA "Hypertensive crisis due to pargyline and metaraminol." Br Med J 5459 (1965): 460-1. [PMID: 14314914]
55	Humberstone PM "Hypertension from cold remedies." Br Med J 1 (1969): 846. [PMID: 5813090]
56	Hunter KR, Boakes AJ, Laurence DR, Stern GM "Monoamine oxidase inhibitors and L-dopa." Br Med J 3 (1970): 388. [PMID: 5451592]
57	King MH, Richards DW "Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy." Am J Ophthalmol 110 (1990): 308-9. [PMID: 2204271]
58	Kraft KE, Dore FH "Computerized drug interaction programs: how reliable?." JAMA 275 (1996): 1087. [PMID: 8601924]
59	Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10. [PMID: 6630590]
60	Lefebvre H, Noblet C, Morre N, Wolf LM "Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline." Clin Endocrinol (Oxf) 42 (1995): 95-8. [PMID: 7889639]
61	Mason AM, Buckle RM ""Cold" cures and monoamine-oxidase inhibitors." Br Med J 1 (1969): 845-6. [PMID: 5813089]
62	Nordlund JR, Pasquale LR, Robin AL, Rudikoff MT, Ordman J, Chen KS, Walt J "The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine." Arch Ophthalmol 113 (1995): 77-83. [PMID: 7826297]
63	Paykel ES "Hallucinosis on combined methyldopa and pargyline." Br Med J 1 (1966): 803. [PMID: 5910115]
64	Pekdemir M, Yanturali S, Karakus G "More than just an ocular solution." Emerg Med J 22 (2005): 753-4. [PMID: 16189050]
65	Product Information. Aldomet (methyldopa). Merck & Co, Inc, West Point, PA.
66	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
67	Product Information. Iopidine (apraclonidine). Alcon Laboratories Inc, Fort Worth, TX.
68	Product Information. Mirvaso (brimonidine topical). Galderma Laboratories Inc, Cranbury, NJ.
69	Product Information. Parcopa (carbidopa-levodopa). Schwarz Pharma, Mequon, WI.
70	Product Information. Sinemet (carbidopa-levodopa). DuPont Pharmaceuticals, Wilmington, DE.
71	Product Information. Stalevo 50 (carbidopa/entacapone/levodopa). Novartis Pharmaceuticals, East Hanover, NJ.
72	Product Information. Tyzine (tetrahydrozoline). Kenwood Laboratories, Fairfield, NJ.
73	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
74	Sharpe J, Marquez-Julio A, Ashby P "Idiopathic orthostatic hypotension treated with levodopa and MAO inhibitor: a preliminary report." Can Med Assoc J 107 (1972): 296-300. [PMID: 5056115]
75	Sjoerdsma A "Catecholamine-drug interactions in man." Pharmacol Rev 18 (1966): 673-83. [PMID: 5904180]
76	Teychenne PF, Calne DB, Lewis PJ, Findley LJ "Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic amino acid decarboxylase." Clin Pharmacol Ther 18 (1975): 273-7. [PMID: 1164817]
77	van Rossum JM "Potential danger of monoamineoxidase inhibitors and a-methyldopa." Lancet 1 (1963): 950-1. [PMID: 13975251]
78	van Rossum JM, Hurkmans JA "Reversal of the effect of a-Methyldopa by monamine oxidase inhibitors." J Pharm Pharmacol 15 (1963): 493-9. [PMID: 14059015]
79	Product Information. Ultram (tramadol). McNeil Pharmaceutical, Raritan, NJ.
80	Gardiner JS, Blough D, Drinkard CR, et al. "Tramadol and seizures: a surveillance study in a managed care population." Pharmacotherapy 20 (2000): 1423-31. [PMID: 11130214]
81	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
82	Product Information. Firdapse (amifampridine). Catalyst Pharmaceuticals, Inc., Coral Gables, FL.
83	Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656
84	Kajiyama Y, Fujii K, Takeuchi H, Manabe Y "Ginkgo seed poisoning." Pediatrics 109 (2002): 325-7. [PMID: 11826216]
85	Granger AS "Ginkgo biloba precipitating epileptic seizures." Age Ageing 30 (2001): 523-5. [PMID: 11742783]
86	Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11. [PMID: 9818800]
87	Spinella M "Herbal medicines and epilepsy: the potential for benefit and adverse effects." Epilepsy Behav 2 (2001): 524-32. [PMID: 12609386]
88	Gregory PJ "Seizure associated with Ginkgo biloba?." Ann Intern Med 134 (2001): 344. [PMID: 11182853]
89	Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE "Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder." Epilepsia 47 (2006): 323-9. [PMID: 16499756]
90	Miwa H, Iijima M, Tanaka S, Mizuno Y "Generalized convulsions after consuming a large amount of Gingko nuts." Epilepsia 42 (2001): 280-1. [PMID: 11240603]
91	Kupiec T, Raj V "Fatal seizures due to potential herb-drug interactions with Ginkgo biloba." J Anal Toxicol 29 (2005): 755-8. [PMID: 16419414]
92	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
93	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
94	Product Information. AdreView (iobenguane I-123). GE Healthcare, Princeton, NJ.
95	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
96	Salik JM, Kurtin P "Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome." Am J Gastroenterol 80 (1985): 177-9. [PMID: 2983533]
97	Product Information. Azilect (rasagiline). Teva Pharmaceuticals USA, North Wales, PA.
98	Smookler S, Barmudez AJ "Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant." Ann Emerg Med 11 (1982): 482-4. [PMID: 7114595]
99	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
100	Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
101	Fenwick MJ, Muwanga CL "Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline." J Accid Emerg Med 17 (2000): 143-4. [PMID: 10718244]
102	Product Information. Xadago (safinamide). US WorldMeds LLC, Louisville , KY.
103	Thompson DS, Sweet RA, Marzula K, Peredes JC "Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient." J Clin Psychopharmacol 17 (1997): 322-3. [PMID: 9241014]
104	Cox R, Krupnick J, Bush N, Houpt A "Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder." J Miss State Med Assoc 41 (2000): 690-2. [PMID: 10974795]
105	Product Information. Kwell (lindane). Reed and Carnrick, Jersey City, NJ.
106	Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
107	Product Information. ProAmatine (midodrine). Roberts Pharmaceutical Corporation, Eatontown, NJ.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence